From the Department of Cardiology (Adel, Jorfi, Mombeini, Fazeli), from the Atherosclerosis Research Center (Adel, Jorfi, Mombeini), and from the Department of Internal Medicine (Rashidi), Ahvaz Jundishapur University of Medical Sciences, Imam Khomeini Hospital, Ahvaz, Iran.
Saudi Med J. 2022 May;43(5):458-464. doi: 10.15537/smj.2022.43.5.20220018.
To study the effects of low dose of empagliflozin on improving outcomes in diabetic patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI).
This double-blind controlled clinical trial was carried out on 93 diabetic patients (56 males and 37 females, mean age of 56.55 years) with ACS who underwent PCI at 2 university teaching hospitals in 2020, Ahvaz, Iran. The patients were randomly assigned to receive empagliflozin (10 mg once daily) or placebo at similar doses for 6 months after PCI. In addition, to standard treatments with another hypoglycemic agent. Cardiovascular outcomes (including all-cause mortality, coronary revascularization, rehospitalization due to unstable angina, hospitalization due to heart failure, cardiovascular death, non-fetal myocardial infarction, and non-fetal stroke) were evaluated during period of 6 months follow-up after the empagliflozin treatment.
There was no significant difference between the low dose empagliflozin and placebo groups after treatment in terms of cardiovascular mortality (2.2% versus [vs.] 4.2%; =0.598), rehospitalization due to unstable angina (4.5% vs. 8.7%; =0.433), and coronary revascularization (2.2% vs. 0%; =0.312).
The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.
研究低剂量恩格列净对经皮冠状动脉介入治疗（PCI）后合并急性冠状动脉综合征（ACS）的糖尿病患者结局的改善作用。
这是一项在伊朗阿瓦士的 2 所大学教学医院进行的双盲对照临床试验，纳入了 2020 年接受 PCI 的 93 例（男 56 例，女 37 例，平均年龄 56.55 岁）合并 ACS 的糖尿病患者。患者被随机分配接受恩格列净（10 mg 每日 1 次）或等剂量安慰剂治疗，疗程为 PCI 后 6 个月。此外，还接受另一种降糖药物的标准治疗。在恩格列净治疗后 6 个月的随访期间，评估心血管结局（包括全因死亡率、冠状动脉血运重建、因不稳定型心绞痛再住院、因心力衰竭住院、心血管死亡、非致死性心肌梗死和非致死性卒中等）。
治疗后，低剂量恩格列净组与安慰剂组在心血管死亡率（2.2% vs. 4.2%；=0.598）、因不稳定型心绞痛再住院（4.5% vs. 8.7%；=0.433）和冠状动脉血运重建（2.2% vs. 0%；=0.312）方面无显著差异。
这项研究结果表明，在 PCI 后合并 ACS 的糖尿病患者的标准治疗中加入低剂量恩格列净，在 6 个月内不会显著降低不良心血管结局的发生风险。
